Distribution of Curcumin and THC in Peripheral Blood Mononuclear Cells Isolated from Healthy Individuals and Patients with Chronic Lymphocytic Leukemia.

Bolger, GT, Licollari, A, Tan, A, Greil, R, Pleyer, L, Vcelar, B, Majeed, M, Sordillo, P. Anticancer Res. 2018, 38(1): 12-130.

Functional and clinical relevance of VLA-4 (CD49d/CD29) in ibrutinib-treated chronic lymphocytic leukemia.

Tissino, E, Benedetti, D, Herman, SEM, Ten Hacken, E, Ahn, IE, Chaffee, KG, Rossi, FM, Dal Bo, M, Bulian, P, Bomben, R, Bayer, E, Härzschel, A, Gutjahr, JC, Postorino, M, Santinelli, E, Ayed, A, Zaja, F, Chiarenza, A, Pozzato, G, Chigaev, A, Sklar, LA, Burger, JA, Ferrajoli, A, Shanafelt, TD, Wiestner, A, Del Poeta, G, Hartmann, TN, Gattei, V, Zucchetto, A. J Exp Med. 2018.

Microenvironment-induced CD44v6 promotes early disease progression in chronic lymphocytic leukemia.

Gutjahr, JC, Szenes, E, Tschech, L, Asslaber, D, Schlederer, M, Roos, S, Yu, X, Girbl, T, Sternberg, C, Egle, A, Aberger, F, Alon, R, Kenner, L, Greil, R, Orian-Rousseau, V, Hartmann, TN. Blood. 2018.

Sidedness and TP53 mutations impact OS in anti-EGFR but not anti-VEGF treated mCRC – an analysis of the KRAS registry of the AGMT (Arbeitsgemeinschaft Medikamentöse Tumortherapie).

Huemer, F, Thaler, J, Piringer, G, Hackl, H, Pleyer, L, Hufnagl, C, Weiss, L, Greil, R. BMC Cancer. 2018, 18(1): 11.

PET-guided treatment in patients with advanced-stage Hodgkins lymphoma (HD18): final results of an open-label, international, randomised phase 3 trial by the German Hodgkin Study Group.

Borchmann, P, Goergen, H, Kobe, C, Lohri, A, Greil, R, Eichenauer, DA, Zijlstra, JM, Markova, J, Meissner, J, Feuring-Buske, M, Hüttmann, A, Dierlamm, J, Soekler, M, Beck, HJ, Willenbacher, W, Ludwig, WD, Pabst, T, Topp, MS, Hitz, F, Bentz, M, Keller, UB, Kühnhardt, D, Ostermann, H, Schmitz, N, Hertenstein, B, Aulitzky, W, Maschmeyer, G, Vieler, T, Eich, H, Baues, C, Stein, H, Fuchs, M, Kuhnert, G, Diehl, V, Dietlein, M, Engert, A. Lancet. 2018, 390(10114): 2790-2802.

Establishment and validation of a novel risk model for estimating time to first treatment in 120 patients with chronic myelomonocytic leukaemia.

Huemer, F, Weiss, L, Faber, V, Neureiter, D, Egle, A, Geissler, K, Voskova, D, Zebisch, A, Burgstaller, S, Pichler, A, Stauder, R, Sperr, W, Lang, A, Pfeilstöcker, M, Machherndl-Spandl, S, Stampfl, M, Greil, R, Pleyer, L. Wien Klin Wochenschr. 2018.

Clonal evolution and heterogeneity in metastatic head and neck cancer-An analysis of the Austrian Study Group of Medical Tumour Therapy study group.

Melchardt, T, Magnes, T, Hufnagl, C, Thorner, AR, Ducar, M, Neureiter, D, Tränkenschuh, W, Klieser, E, Gaggl, A, Rösch, S, Rasp, G, Hartmann, TN, Pleyer, L, Rinnerthaler, G, Weiss, L, Greil, R, Egle, A. Eur J Cancer. 2018, 93:69-78.

Incidence and risk factors for relapses in HIV-associated non-Hodgkin-lymphoma as observed in the German HIV-related lymphoma cohort study.

Schommers, P, Gillor, D, Hentrich, M, Wyen, C, Wolf, T, Oette, M, Zoufaly, A, Wasmuth, JC, Bogner, JR, Müller, M, Esser, S, Schleicher, A, Jensen, B, Stoehr, A, Behrens, G, Schultze, A, Siehl, J, Thoden, J, Taylor, N, Hoffmann, C. Haematologica. 2018.

The multiple myeloma treatment landscape: international guideline recommendations and clinical practice in Europe.

Cavo, M, Terpos, E, Bargay, J, Einsele, H, Cavet, J, Greil, R, de Wit, E. Expert Rev Hematol. 2018, 11(3):219-237.

Real life experience with frontline azacitidine in a large series of older adults with acute myeloid leukemia stratified by MRC/LRF score: results from the expanded international E-ALMA series (E-ALMA+).

Falantes, J, Pleyer, L, Thépot, S, Almeida, AM, Maurillo, L, Martínez-Robles, V, Stauder, R, Itzykson, R, Pinto, R, Venditti, A, Bargay, J, Burgstaller, S, Martínez, MP, Seegers, V, Cortesão, E, Foncillas, MÁ, Gardin, C, Montesinos, P, Musto, P, Fenaux, P, Greil, R, Sanz, MA, Ramos, F, Leuk Lymphoma. 2018, 59(5):1113-1120.